PFS Foundation News

Possible Epigenetic Changes in PFS Patients Is Focus of New Clinical Study

SOMERSET, N.J., Jan. 29, 2018 – The Post-Finasteride Syndrome Foundation today announced Phase II of the clinical research on post-finasteride syndrome (PFS) being conducted at the University of Milano. Led by Roberto Cosimo Melcangi, Ph.D., head of the Neuroendocrinology Unit in the Department of Pharmacological and Biomolecular Sciences, the new study will evaluate: —In PFS […]

2017 PFS Foundation Annual Address

Aug. 4, 2017 Dear Friends: Recent events in Europe and Asia have given me hope that, before this decade is out, we’ll see the day when no man on earth is prescribed finasteride without ample warning of its many potential dangers. On May 24, the UK’s equivalent of the US Food and Drug Administration, the […]

Regulatory Update: ‘Muscle-related Disorders’ Added to Canadian Finasteride Label in Response to Report by FDA-equivalent Agency

July 28, 2018 Dear Friends: Canada has taken an important first step toward keeping its citizens apprised of finasteride’s many potentially serious and persistent side effects. In the June edition of its Health Product InfoWatch, Health Canada (Canada’s version of the US Food and Drug Administration) reported that “New information regarding the risk of muscle-related […]

Peripheral Nervous System Involved in PFS Patients with Severe ED, New Study Demonstrates

SOMERSET, N.J., April 18, 2017 – Post-finasteride syndrome (PFS) patients suffer from altered levels of critical brain-function regulators, including neuroactive steroids, according to a new clinical study published in The Journal of Steroid Biochemistry and Molecular Biology. Titled Neuroactive Steroid Levels and Psychiatric and Andrological Features in Post-Finasteride Patients, the three-year study also uncovered evidence […]

Regulatory Update: MHRA Issues Drug Safety Update on Finasteride

May 26, 2017 Dear Friends: The UK’s equivalent of the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory Agency (MHRA), has issued a drug safety update on finasteride. The May 24 document, titled Finasteride: rare reports of depression and suicidal thoughts, states: Some men have reported episodes of depressive illness in association with […]